FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249432840> ?p ?o ?g. }

• W4249432840 endingPage "1212" @default.
• W4249432840 startingPage "1212" @default.
• W4249432840 abstract "Catching up with the rest of the world, the European Commission last week licensed the first human papillomavirus (HPV) vaccine, Gardasil, for use in children aged 9–15 years and women aged 16–26 years. The vaccine offers protection against HPV types 16 and 18, which are responsible for 70% of all cervical cancers, and types 6 and 11, which cause about 90% of cases of genital warts.Following earlier approval by the US Food and Drug Administration of the vaccine in girls and women, the Michigan Senate passed a bill on Sept 21, ruling that all girls entering the sixth grade of school (11–12 years old) should be immunised. This is the first legislation of its kind in the USA, and a decision from which the EU member states should take heed.However, despite these welcome developments, key questions remain. Who will fund these routine immunisations? Reassuringly, Gardasil has been added to the US Vaccines for Children Program that provides free immunisations to those that most need them, and the UK Department of Health is also considering government funding. But, even with these resources, the debate remains over who should be immunised. Contrary to the FDA's recommendations, there is growing support for the vaccination of both boys and girls. Modelling studies have shown that a female-specific approach would be only 60–75% as effective at reducing HPV prevalence in women as strategies that target both sexes. And other benefits of the vaccine should not be overlooked; it also offers protection against genital warts and malignancies such as anal cancer, which affect both sexes. Furthermore, previous gender-specific initiatives have not always succeeded—in 1995, the UK's rubella immunisation programme was modified after 25 years to include boys as well as girls, after a rise in the number of pregnant women contracting rubella.For effective and long-term eradication of HPV, all adolescents must be immunised. Data from the vaccine trials in boys are urgently needed; in the mean time, EU member states should lead by making the vaccinations mandatory for all girls aged 11–12 years. Catching up with the rest of the world, the European Commission last week licensed the first human papillomavirus (HPV) vaccine, Gardasil, for use in children aged 9–15 years and women aged 16–26 years. The vaccine offers protection against HPV types 16 and 18, which are responsible for 70% of all cervical cancers, and types 6 and 11, which cause about 90% of cases of genital warts. Following earlier approval by the US Food and Drug Administration of the vaccine in girls and women, the Michigan Senate passed a bill on Sept 21, ruling that all girls entering the sixth grade of school (11–12 years old) should be immunised. This is the first legislation of its kind in the USA, and a decision from which the EU member states should take heed. However, despite these welcome developments, key questions remain. Who will fund these routine immunisations? Reassuringly, Gardasil has been added to the US Vaccines for Children Program that provides free immunisations to those that most need them, and the UK Department of Health is also considering government funding. But, even with these resources, the debate remains over who should be immunised. Contrary to the FDA's recommendations, there is growing support for the vaccination of both boys and girls. Modelling studies have shown that a female-specific approach would be only 60–75% as effective at reducing HPV prevalence in women as strategies that target both sexes. And other benefits of the vaccine should not be overlooked; it also offers protection against genital warts and malignancies such as anal cancer, which affect both sexes. Furthermore, previous gender-specific initiatives have not always succeeded—in 1995, the UK's rubella immunisation programme was modified after 25 years to include boys as well as girls, after a rise in the number of pregnant women contracting rubella. For effective and long-term eradication of HPV, all adolescents must be immunised. Data from the vaccine trials in boys are urgently needed; in the mean time, EU member states should lead by making the vaccinations mandatory for all girls aged 11–12 years." @default.
• W4249432840 created "2022-05-12" @default.
• W4249432840 creator A5085953656 @default.
• W4249432840 date "2006-10-01" @default.
• W4249432840 modified "2023-10-05" @default.
• W4249432840 title "Should HPV vaccines be mandatory for all adolescents?" @default.
• W4249432840 doi "https://doi.org/10.1016/s0140-6736(06)69494-4" @default.
• W4249432840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17027705" @default.
• W4249432840 hasPublicationYear "2006" @default.
• W4249432840 type Work @default.
• W4249432840 citedByCount "10" @default.
• W4249432840 countsByYear W42494328402017 @default.
• W4249432840 crossrefType "journal-article" @default.
• W4249432840 hasAuthorship W4249432840A5085953656 @default.
• W4249432840 hasConcept C121608353 @default.
• W4249432840 hasConcept C126322002 @default.
• W4249432840 hasConcept C138885662 @default.
• W4249432840 hasConcept C147483822 @default.
• W4249432840 hasConcept C17744445 @default.
• W4249432840 hasConcept C187212893 @default.
• W4249432840 hasConcept C199539241 @default.
• W4249432840 hasConcept C203014093 @default.
• W4249432840 hasConcept C22070199 @default.
• W4249432840 hasConcept C2776983459 @default.
• W4249432840 hasConcept C2777265743 @default.
• W4249432840 hasConcept C2777351106 @default.
• W4249432840 hasConcept C2778137410 @default.
• W4249432840 hasConcept C2778220009 @default.
• W4249432840 hasConcept C2778308922 @default.
• W4249432840 hasConcept C2778580637 @default.
• W4249432840 hasConcept C2780009117 @default.
• W4249432840 hasConcept C2780801004 @default.
• W4249432840 hasConcept C29456083 @default.
• W4249432840 hasConcept C2994532551 @default.
• W4249432840 hasConcept C3013748606 @default.
• W4249432840 hasConcept C3018890749 @default.
• W4249432840 hasConcept C41895202 @default.
• W4249432840 hasConcept C512399662 @default.
• W4249432840 hasConcept C71924100 @default.
• W4249432840 hasConcept C99454951 @default.
• W4249432840 hasConceptScore W4249432840C121608353 @default.
• W4249432840 hasConceptScore W4249432840C126322002 @default.
• W4249432840 hasConceptScore W4249432840C138885662 @default.
• W4249432840 hasConceptScore W4249432840C147483822 @default.
• W4249432840 hasConceptScore W4249432840C17744445 @default.
• W4249432840 hasConceptScore W4249432840C187212893 @default.
• W4249432840 hasConceptScore W4249432840C199539241 @default.
• W4249432840 hasConceptScore W4249432840C203014093 @default.
• W4249432840 hasConceptScore W4249432840C22070199 @default.
• W4249432840 hasConceptScore W4249432840C2776983459 @default.
• W4249432840 hasConceptScore W4249432840C2777265743 @default.
• W4249432840 hasConceptScore W4249432840C2777351106 @default.
• W4249432840 hasConceptScore W4249432840C2778137410 @default.
• W4249432840 hasConceptScore W4249432840C2778220009 @default.
• W4249432840 hasConceptScore W4249432840C2778308922 @default.
• W4249432840 hasConceptScore W4249432840C2778580637 @default.
• W4249432840 hasConceptScore W4249432840C2780009117 @default.
• W4249432840 hasConceptScore W4249432840C2780801004 @default.
• W4249432840 hasConceptScore W4249432840C29456083 @default.
• W4249432840 hasConceptScore W4249432840C2994532551 @default.
• W4249432840 hasConceptScore W4249432840C3013748606 @default.
• W4249432840 hasConceptScore W4249432840C3018890749 @default.
• W4249432840 hasConceptScore W4249432840C41895202 @default.
• W4249432840 hasConceptScore W4249432840C512399662 @default.
• W4249432840 hasConceptScore W4249432840C71924100 @default.
• W4249432840 hasConceptScore W4249432840C99454951 @default.
• W4249432840 hasIssue "9543" @default.
• W4249432840 hasLocation W42494328401 @default.
• W4249432840 hasLocation W42494328402 @default.
• W4249432840 hasOpenAccess W4249432840 @default.
• W4249432840 hasPrimaryLocation W42494328401 @default.
• W4249432840 hasRelatedWork W11223332 @default.
• W4249432840 hasRelatedWork W1568413287 @default.
• W4249432840 hasRelatedWork W1644677752 @default.
• W4249432840 hasRelatedWork W1986099429 @default.
• W4249432840 hasRelatedWork W2012319830 @default.
• W4249432840 hasRelatedWork W25819948 @default.
• W4249432840 hasRelatedWork W2770979894 @default.
• W4249432840 hasRelatedWork W2944410044 @default.
• W4249432840 hasRelatedWork W4251651447 @default.
• W4249432840 hasRelatedWork W4303685087 @default.
• W4249432840 hasVolume "368" @default.
• W4249432840 isParatext "false" @default.
• W4249432840 isRetracted "false" @default.
• W4249432840 workType "article" @default.